DEF: Cingulate Seeks Shareholder Vote on $12M Private Placement

Cingulate Inc. calls a Special Meeting to approve the conversion of preferred stock and exercise of warrants from a recent $12 million private placement, crucial for Nasdaq compliance and future capital.

Summary

• A Special Meeting of Stockholders is scheduled for March 24, 2026, to vote on two key proposals: the Issuance Proposal and the Adjournment Proposal.
• The Issuance Proposal seeks stockholder approval for the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or the exercise of warrants, stemming from a securities purchase agreement dated January 27, 2026.
• This approval is necessary to comply with Nasdaq Listing Rule 5635(b), which requires a vote for issuances that could result in a change of control (20% or more ownership).
• The private placement, which closed on February 6 and 13, 2026, generated approximately $12.0 million in gross proceeds.
• The proceeds are intended for working capital and general corporate purposes.
• Failure to approve the Issuance Proposal would prevent the conversion of preferred stock and exercise of warrants, leading to ongoing 12% cumulative dividends on preferred stock and delaying the receipt of $9.4 million from warrant exercises.
• The Board unanimously recommends voting FOR both the Issuance Proposal and the Adjournment Proposal.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the private placement has already secured capital, the need for shareholder approval to fully operationalize the conversion of preferred stock and exercise of warrants introduces a procedural hurdle. Approval would unlock further capital and simplify the capital structure, but also entails significant dilution. Failure to approve would be a clear negative, leading to ongoing costs and missed capital.

Positives

• The private placement has already secured approximately $12.0 million in gross proceeds for working capital and general corporate purposes.
• Approval of the Issuance Proposal would unlock an additional $9.4 million in potential proceeds from warrant exercises.
• The Lead Investor, Falcon Creek Capital Advisor LLC, will have significant board representation (two out of seven directors) upon approval, potentially bringing strategic guidance.
• Elimination of the 12% cumulative dividend and senior liquidation preference of the Preferred Stock upon conversion, reducing future financial obligations and simplifying the capital structure.

Negatives

• Failure to obtain stockholder approval for the Issuance Proposal would require the company to hold additional stockholder meetings every three months, incurring significant costs and diverting management resources.
• The Preferred Stock will continue to accrue 12% cumulative annual dividends if not converted, compounding potential dilution over time and maintaining a senior liquidation preference.
• The conversion of Preferred Stock and exercise of Warrants, if approved, will result in approximately 19.1% dilution to existing common stockholders.
• The Lead Investor and affiliates would own approximately 32.7% of outstanding common stock on an as-converted basis, which is a significant concentration of ownership.

Risks

• Risk of significant management time and resources being diverted to repeated stockholder meetings if the Issuance Proposal is not approved.
• Risk of compounding dilution to common stockholders due to the accrual of 12% cumulative annual dividends on outstanding Preferred Stock if conversion is delayed.
• Risk of common stockholders receiving significantly reduced or no distributions in a liquidation event if Preferred Stock remains outstanding with its senior liquidation preference.
• Risk of not receiving $9.4 million in potential proceeds from warrant exercises if stockholder approval is not obtained, impacting the company's ability to fund operations and advance business objectives.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes. Approval of the Issuance Proposal is crucial for unlocking additional capital from warrant exercises and avoiding ongoing costs and complexities associated with the Preferred Stock.

Management Comments

• The Board has determined that the Private Placement is in our best interests and the best interest of our stockholders because proceeds from the Private Placement and potential proceeds from the exercise of the Warrant provides us with additional capital.
• The Board unanimously recommends that you vote FOR the approval of the Issuance Proposal.
• The Board unanimously recommends that you vote FOR the Adjournment Proposal.

Industry Context

StockSavvy.ai notes that companies often utilize private placements of convertible securities and warrants to raise capital, especially in growth-oriented or capital-intensive sectors. Such transactions typically require shareholder approval to ensure compliance with exchange listing rules and to manage potential dilution, a common practice in the biotechnology and pharmaceutical industries where Cingulate operates.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Certain of the company's officers, directors, and other affiliates participated in the Private Placement, acquiring 98,250 shares of common stock and 78,598 Warrant Shares. These individuals' ability to convert their warrants is contingent on stockholder approval of the Issuance Proposal.

Stakeholder Impact

• **Shareholders**: Face potential dilution of approximately 19.1% if the Issuance Proposal is approved, but also benefit from the company securing additional capital for operations. Failure to approve would lead to ongoing costs and compounding dilution from preferred stock dividends.
• **Preferred Stockholders/Warrant Holders**: Their ability to convert preferred stock into common stock and exercise warrants is contingent on stockholder approval. Without approval, their securities remain restricted, and preferred stockholders continue to accrue 12% cumulative dividends.
• **Management**: Will incur significant time and resource costs if the Issuance Proposal is not approved, due to repeated special meetings. Approval simplifies the capital structure and provides additional funding for business objectives.
• **Nasdaq**: The company is seeking approval to comply with Nasdaq Listing Rule 5635(b), ensuring continued listing compliance.

Next Steps

• Stockholders to vote on the Issuance Proposal and Adjournment Proposal at the Special Meeting on March 24, 2026.
• If the Issuance Proposal is not approved, the company is required to hold additional stockholder meetings every three months until approval is obtained.
• Upon stockholder approval of the Issuance Proposal, the Preferred Stock will automatically convert into common stock, and warrants will become exercisable.
• The company will file a registration statement with the SEC on or prior to the 60th calendar day following the last closing date of the Private Placement to register the resale of the securities.

Key Dates

Recommendation

The filing primarily concerns a procedural vote to ratify a completed private placement and enable the conversion/exercise of associated securities. While approval would unlock additional capital and simplify the capital structure, it also entails significant dilution. Failure to approve would be detrimental due to ongoing costs and missed capital. Given that the capital raise itself has already occurred, the immediate impact is more about resolving a compliance and operational hurdle rather than a new financial event. Investors should 'hold' as the outcome of the vote is expected to be positive, but the dilution is already factored into the market's understanding of the capital structure.

Keywords

Cingulate Inc., Special Meeting, Proxy Statement, Nasdaq Listing Rule 5635(b), Private Placement, Convertible Preferred Stock, Warrants, Stockholder Approval, Dilution, Capital Raise, Corporate Governance, Falcon Creek Capital